ArticleClinical, cosmetic and investigational dermatology2025
Case Series and Literature Review on Tofacitinib for Treating Severe Alopecia Areata.
Article in Clinical, cosmetic and investigational dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- JAK Inhibitors for Alopecia Areata: Approved Therapies, Efficacy, and Unanswered Questions.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alopecia areata (AA) is an autoimmune-mediated, non-scarring hair loss disorder. With the advancement of alopecia treatment research, the efficacy of Janus kinase (JAK) inhibitors in the clinical management of AA has been increasingly evaluated. Objective: This study reports the efficacy and safety of tofacitinib in the treatment of severe AA and presents a literature review on tofacitinib in AA. Methods: Collect patient information on severe AA treated at a tertiary hospital from April 2023 to May 2024, and analyze their clinical treatment outcomes. Results: All five collected patients met the criteria for refractory alopecia areata. Three of these patients achieved favorable therapeutic outcomes with mild adverse reactions, consistent with current research findings. Conclusion: This study supports the efficacy and safety of tofacitinib in AA treatment, providing further clinical evidence for its application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.